ArticleInternational journal of laboratory hematology2026
Two Novel PKLR Variants in Pyruvate Kinase Deficiency: Insights From Clinical, Molecular and Functional Analysis.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPyruvate kinase deficiency (PKD) is a rare cause of hereditary non-spherocytic hemolytic anemia. This study reports the clinical and molecular characterization of three pediatric PKD cases, focusing on two novel PKLR variants.
methodsClinical and laboratory data were reviewed. PKLR gene was analyzed by next-generation sequencing and validated by Sanger sequencing. Pathogenicity was predicted using in silico tools and ACMG criteria. Structural consequences were modeled with AlphaFold3 and Chimera-X. Functional impact was assessed by Western blot and immunofluorescence in transfected 293T cells.
resultsAll patients presented with neonatal hemolytic anemia. Genetic analysis revealed compound heterozygosity for PKLR mutations. Two novel variants were identified: c.1708G>A (p.Val570Met) and c.1430C>T (p.Thr477Ile). In silico analysis predicted both as damaging. Structural modeling suggested p.Val570Met disrupts inter-subunit hydrogen bonds, while p.Thr477Ile lies within the fructose-1,6-bisphosphate (FBP) binding loop. In vitro, both mutants showed reduced protein expression compared to wild-type but normal cytoplasmic localization.
conclusionWe identified two novel PKLR variants expanding the mutational spectrum of PKD. Integrated analysis suggests p.Val570Met may impair tetramer stability, whereas p.Thr477Ile likely affects allosteric regulation. These findings underscore the value of combining clinical phenotyping with functional studies for accurate variant interpretation in PKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.